AUPH

Voclosporin

Focal Segmental Glomerulosclerosis (FSGS)

Stage (next event)

Expected Date

Phase 2 (Interim Data)

H2 2020

Catalyst Info & Data Links

TITLE: Voclosporin in Focal Segmental Glomerulosclerosis (FSGS) - Interim Results Phase 2

  • ClinicalTrial.gov (NCT03598036): Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis (AURONA™)


WHAT IS THE CATALYST EVENT?


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • H2 2020


PRIOR DATA/EVENTS


PRESS RELEASE

POSTERS


PRESENTATIONS


PUBLICATIONS

MECHANISM OF ACTION 

  • Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action. By inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell mediated immune responses and stabilizes the podocyte in the kidney (see details). 


COMPETITORS

  • Sparsentan - Retrophin, Inc.

  • VAR 200 (2-hydroxypropyl-β-cyclodextrin, or HPβCD) - Variant Pharmaceuticals 

Selective inhibitor of the chemokine receptor CCR2:

MARKET

  • ~ 5400 patients are diagnosed every year (source)

  • ~ 10,000 people living with dialysis or with a kidney transplant due to FSGS (source)

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon